AC Immune SA ACIU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.25
- Day Range
- $2.20–2.27
- 52-Week Range
- $1.68–4.00
- Bid/Ask
- $2.21 / $2.23
- Shares Outstanding
- 101.77M
- Market Cap
- $224.41M
- Volume/Avg
- 183,608 / 260,401
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 48.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.acimmune.com
Valuation
|
Metric
|
ACIU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.81 |
Price/Sales | 48.96 |
Price/Cash Flow | — |
Price/Earnings
ACIU
Financial Strength
|
Metric
|
ACIU
|
|---|---|
Quick Ratio | 0.83 |
Current Ratio | 0.87 |
Interest Coverage | −332.13 |
Quick Ratio
ACIU
Profitability
|
Metric
|
ACIU
|
|---|---|
Return on Assets (Normalized) | −38.03% |
Return on Equity (Normalized) | −106.62% |
Return on Invested Capital (Normalized) | −100.85% |
Return on Assets
ACIU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wtybtwvk | Mbsvhk | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fjkwltqn | Wrbwydv | $67B | |||
| argenx SE ADR
ARGX
| Dvjmbpgl | Vsny | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Nwhyghhx | Skypdc | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Zkbpglvwlp | Tstrnr | $25B | |||
| BioNTech SE ADR
BNTX
| Rksrppbzf | Cygzc | $22B | |||
| Incyte Corp
INCY
| Cxwfyqxk | Pmrnp | $20B | |||
| Moderna Inc
MRNA
| Bcrhtyml | Xqqmg | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Xgbmjxh | Lmr | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Wssfgknjd | Vkdg | $13B |
United States